[ad_1]
New York, December 10, 2021 (Global News Agency) – Pomerantz LLP announced that it has acquired Organogenesis Holdings Inc. (“Organogenesis” or “Company”) (NASDAQ:Olgo) And some of its senior staff. The class action was filed in the U.S. District Court for the Eastern District of New York and documented under 21-cv-06845, representing a class consisting of all individuals and entities other than the defendant who purchased or otherwise obtained organogenesis securities March 2021 From 17 to October 11, 2021 (both dates inclusive) (the “class action period”), seek compensation for losses caused by the defendant’s violation of the Federal Securities Law, and seek pursuant to Sections 10(b) and 20(a) Remedy)’s Securities Exchange Act of 1934 (“Exchange Act”) and Article 10b-5 promulgated under the Act against companies and certain senior officials.
If you are a shareholder who purchased organ genetic securities during the class action, you must request the court to appoint you as the lead plaintiff of the class action before February 8, 2022.A copy of the complaint is available at the following URL www.pomerantzlaw.com. To discuss this operation, please contact Robert S. Willoughby newaction@pomlaw.com …
The full story can be found on Benzinga.com
[ad_2]
Source link
